SG10201912387PA - Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies - Google Patents

Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies

Info

Publication number
SG10201912387PA
SG10201912387PA SG10201912387PA SG10201912387PA SG10201912387PA SG 10201912387P A SG10201912387P A SG 10201912387PA SG 10201912387P A SG10201912387P A SG 10201912387PA SG 10201912387P A SG10201912387P A SG 10201912387PA SG 10201912387P A SG10201912387P A SG 10201912387PA
Authority
SG
Singapore
Prior art keywords
blockade
immunotherapy
expression
chimeric antigen
antigen receptors
Prior art date
Application number
SG10201912387PA
Inventor
Dario Campana
Natasha Vinanica
Takahiro Kamiya
Yi Png
Original Assignee
Nat Univ Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Univ Singapore filed Critical Nat Univ Singapore
Publication of SG10201912387PA publication Critical patent/SG10201912387PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A61K39/464412—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/04—Fusion polypeptide containing a localisation/targetting motif containing an ER retention signal such as a C-terminal HDEL motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/05—Fusion polypeptide containing a localisation/targetting motif containing a GOLGI retention signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Bioinformatics & Cheminformatics (AREA)
SG10201912387PA 2016-11-22 2017-11-22 Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies SG10201912387PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662425398P 2016-11-22 2016-11-22
US201762543696P 2017-08-10 2017-08-10

Publications (1)

Publication Number Publication Date
SG10201912387PA true SG10201912387PA (en) 2020-02-27

Family

ID=62193475

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201903830TA SG11201903830TA (en) 2016-11-22 2017-11-22 Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies
SG10201912387PA SG10201912387PA (en) 2016-11-22 2017-11-22 Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201903830TA SG11201903830TA (en) 2016-11-22 2017-11-22 Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies

Country Status (9)

Country Link
US (3) US11440958B2 (en)
EP (1) EP3545082A4 (en)
JP (2) JP2019536480A (en)
KR (1) KR20190085528A (en)
CN (1) CN110268049A (en)
AU (2) AU2017363278B2 (en)
CA (1) CA3043752A1 (en)
SG (2) SG11201903830TA (en)
WO (1) WO2018098306A1 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016216149B2 (en) 2015-02-06 2022-03-31 National University Of Singapore Methods for enhancing efficacy of therapeutic immune cells
KR20190085528A (en) * 2016-11-22 2019-07-18 싱가포르국립대학교 Blocking chimeric antigen receptors and CD7 expression for immunotherapy of T-cell malignancies
US10227576B1 (en) 2018-06-13 2019-03-12 Caribou Biosciences, Inc. Engineered cascade components and cascade complexes
CN112292448A (en) * 2018-10-31 2021-01-29 南克维斯特公司 NK cell depletion of CD19-CAR from CD 19-positive lymphoid malignancies
SG11202104334SA (en) * 2018-11-14 2021-05-28 MediSix Therapeutics Pte Ltd Two-gene vectors for generating car-t cells and uses thereof
CN109652379B (en) * 2018-12-29 2022-08-16 博生吉医药科技(苏州)有限公司 CD7 chimeric antigen receptor modified NK-92MI cell and application thereof
SG11202112382WA (en) 2019-05-07 2021-12-30 Gracell Biotechnologies Shanghai Co Ltd Engineered immune cell targeting bcma and use thereof
GB201914611D0 (en) * 2019-10-09 2019-11-20 Autolus Ltd Engineered immune cell
BR112022006923A2 (en) * 2019-10-11 2022-07-05 Univ Leland Stanford Junior RECOMBINANT POLYPEPTIDES FOR ADJUSTABLE CELL LOCALIZATION
JP2023502986A (en) * 2019-11-20 2023-01-26 カルセリックス ピーティーワイ． リミテッド Methods of providing immune cells with enhanced function
WO2021118873A1 (en) * 2019-12-09 2021-06-17 St. Jude Children's Research Hospital, Inc. Method for preparing cd7-negative, cd3-positive t cells
US20210253712A1 (en) * 2020-01-30 2021-08-19 ST Phi Therapeutics Universal T Cells and the Method of Use Thereof
CN114525259A (en) * 2020-11-03 2022-05-24 南京北恒生物科技有限公司 Chimeric antigen receptor targeting CD7 and uses thereof
CN112300282A (en) * 2020-11-03 2021-02-02 南京北恒生物科技有限公司 Humanized antibodies targeting CD7 and uses thereof
AU2021377699A1 (en) 2020-11-13 2023-06-15 Catamaran Bio, Inc. Genetically modified natural killer cells and methods of use thereof
AU2021386367A1 (en) 2020-11-24 2023-06-22 Les Laboratoires Servier Bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
CN113234682B (en) * 2021-01-12 2023-02-21 上海雅科生物科技有限公司 CD 7-targeted engineered immune cell, chimeric antigen receptor, CD7 blocking molecule and application
JP2024505955A (en) * 2021-02-03 2024-02-08 バイオヘン セラピューティクス リミテッド New chimeric antigen receptor and its use
CN112980800A (en) * 2021-03-08 2021-06-18 河北森朗生物科技有限公司 CAR-T cell, construction method and application thereof
CN115044617A (en) * 2021-03-08 2022-09-13 河北森朗生物科技有限公司 Preparation method of CAR T cell, CAR T cell and application thereof
CN112662631B (en) * 2021-03-16 2021-06-29 合源生物科技(天津)有限公司 CAR-T cell perfusion culture method
CN114591444A (en) * 2021-06-08 2022-06-07 北京美康基免生物科技有限公司 Humanized chimeric antigen receptor based on CD7 and application thereof
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023155852A1 (en) * 2022-02-17 2023-08-24 上海优替济生生物医药有限公司 Modified immune effector cells and uses thereof
CN114560943B (en) * 2022-02-28 2022-12-16 先进生物(苏州)有限公司 CD7-CAR-T cell and preparation method and application thereof
WO2023185256A1 (en) * 2022-03-29 2023-10-05 中国医学科学院血液病医院(中国医学科学院血液学研究所) Antibody that specifically binds to cd7 and use thereof in preparing chimeric antigen receptor
CN117004603A (en) * 2022-04-28 2023-11-07 南京北恒生物科技有限公司 Engineered immune cell with CD7 gene knocked out and application thereof
WO2023225359A1 (en) 2022-05-20 2023-11-23 Novartis Ag Antibody-drug conjugates of antineoplastic compounds and methods of use thereof
WO2023223097A1 (en) 2022-05-20 2023-11-23 Novartis Ag Antibody drug conjugates
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2018248A1 (en) 1989-06-07 1990-12-07 Clyde W. Shearman Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
EP1015616A2 (en) 1997-09-19 2000-07-05 Dana Farber Cancer Institute, Inc. Intrabody-mediated control of immune reactions
CA2386270A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
AU2001275474A1 (en) 2000-06-12 2001-12-24 Akkadix Corporation Materials and methods for the control of nematodes
WO2002036142A2 (en) * 2000-11-03 2002-05-10 University Of Vermont And State Agricultural College Compositions for inhibiting grb7
AU2002361390A1 (en) 2001-12-14 2003-06-30 Friedrich-Alexander-Universitaet Erlangen-Nuernberg Anti-cd7 immunotoxin as fusion protein
WO2005017163A2 (en) 2003-08-15 2005-02-24 Imperial College Innovations Limited Phenotypic knockout of cell-surface proteins
US20130266551A1 (en) 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
JP5112863B2 (en) 2004-07-01 2013-01-09 ノヴォ ノルディスク アー／エス Human anti-KIR antibody
EP1814567A4 (en) 2004-10-27 2009-05-06 Medimmune Inc Use of modulators of epha2 and ephrina1 for the treatment and prevention of infections
US20070036773A1 (en) 2005-08-09 2007-02-15 City Of Hope Generation and application of universal T cells for B-ALL
AU2006302254B2 (en) 2005-10-06 2011-05-26 Xencor, Inc. Optimized anti-CD30 antibodies
MX2009008909A (en) 2007-03-01 2009-08-28 Symphogen As Recombinant anti-epidermal growth factor receptor antibody compositions.
EP2185574B1 (en) 2007-09-07 2013-05-08 Agensys, Inc. Antibodies and related molecules that bind to 24p4c12 proteins
BRPI0908508A2 (en) 2008-01-24 2016-03-22 Novo Nordisk As humanized anti-human nkg2a monoclonal antibody
WO2011047146A2 (en) 2009-10-14 2011-04-21 Centocor Ortho Biotech Inc. Methods of affinity maturing antibodies
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
MX347078B (en) * 2010-12-09 2017-04-10 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer.
KR20140127816A (en) 2012-02-22 2014-11-04 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer
ES2728782T3 (en) 2012-05-25 2019-10-28 Univ California Methods and compositions for RNA-directed target DNA modification and for RNA-directed transcription modulation
EP3763810A3 (en) 2012-10-10 2021-07-14 Sangamo Therapeutics, Inc. T cell modifying compounds and uses thereof
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
WO2014093831A2 (en) * 2012-12-14 2014-06-19 Thomson Reuters (Markets) Llc Dynamic function builder
KR101521224B1 (en) * 2012-12-20 2015-05-19 한양대학교 산학협력단 Humanized single chain fragment antibody(scFv) carrier specific for T cell
JP2016503655A (en) 2012-12-27 2016-02-08 アデュロ バイオテック，インコーポレイテッド Signal peptide fusion partner facilitating expression of the antigenic sequence of Listeria, its preparation method and its use
KR20220100093A (en) 2013-02-06 2022-07-14 안트로제네시스 코포레이션 Modified t lymphocytes having improved specificity
CN105874061B (en) 2013-02-26 2021-08-10 纪念斯隆-凯特琳癌症中心 Compositions and methods for immunotherapy
ES2645393T3 (en) 2013-05-29 2017-12-05 Cellectis T lymphocyte manipulation methods for immunotherapy using the RNA-guided Cas nuclease system
MX2016006057A (en) 2013-11-21 2016-11-14 Ucl Business Plc Cell.
CN106029875A (en) 2014-02-14 2016-10-12 塞勒克提斯公司 Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
GB201405845D0 (en) 2014-04-01 2014-05-14 Ucl Business Plc Signalling system
EP3169773B1 (en) 2014-07-15 2023-07-12 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
BR112017007003A2 (en) 2014-10-07 2017-12-19 Cellectis method for modulating carbon-induced immune cell activity
PL3560953T3 (en) 2014-12-24 2024-05-13 Autolus Limited Cell
AU2016216149B2 (en) 2015-02-06 2022-03-31 National University Of Singapore Methods for enhancing efficacy of therapeutic immune cells
PL3261651T3 (en) * 2015-02-27 2022-08-22 Icell Gene Therapeutics Llc Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof
CN107073138B (en) 2015-03-02 2018-06-29 上海斯丹赛生物技术有限公司 Reduce the immunological tolerance induced by PD-L1
CN108472314A (en) 2015-07-31 2018-08-31 明尼苏达大学董事会 The cell and therapy of modification
US20180371052A1 (en) * 2015-12-22 2018-12-27 Icell Gene Therapeutics Llc Chimeric antigen receptors and enhancement of anti-tumor activity
CA3016287A1 (en) 2016-03-04 2017-09-08 Novartis Ag Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
US11390658B2 (en) * 2016-06-06 2022-07-19 St. Jude Children's Research Hospital Anti-CD7 chimeric antigen receptor and method of use thereof
CA2937157A1 (en) 2016-07-25 2018-01-25 Ucl Business Plc Protein-based t-cell receptor knockdown
KR102546839B1 (en) * 2016-08-03 2023-06-23 워싱턴 유니버시티 Gene editing of CAR-T cells for the treatment of T-cell malignancies using chimeric antigen receptors
KR20190085528A (en) 2016-11-22 2019-07-18 싱가포르국립대학교 Blocking chimeric antigen receptors and CD7 expression for immunotherapy of T-cell malignancies
US20190038733A1 (en) 2017-08-10 2019-02-07 National University Of Singapore T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof
SG11202104334SA (en) 2018-11-14 2021-05-28 MediSix Therapeutics Pte Ltd Two-gene vectors for generating car-t cells and uses thereof

Also Published As

Publication number Publication date
US11440958B2 (en) 2022-09-13
US11945865B2 (en) 2024-04-02
AU2017363278B2 (en) 2022-10-27
US20180148506A1 (en) 2018-05-31
US10550183B2 (en) 2020-02-04
WO2018098306A1 (en) 2018-05-31
JP2019536480A (en) 2019-12-19
US20180179280A1 (en) 2018-06-28
AU2022268355A1 (en) 2023-02-09
EP3545082A4 (en) 2020-07-01
WO2018098306A8 (en) 2018-08-23
CN110268049A (en) 2019-09-20
AU2017363278A1 (en) 2019-05-23
JP2023059873A (en) 2023-04-27
CA3043752A1 (en) 2018-05-31
KR20190085528A (en) 2019-07-18
EP3545082A1 (en) 2019-10-02
SG11201903830TA (en) 2019-05-30
US20220348655A1 (en) 2022-11-03

Similar Documents

Publication Publication Date Title
SG10201912387PA (en) Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies
IL281819A (en) Chimeric antigen receptors and methods of making
IL252295A0 (en) Chimeric antigen receptors and methods of use thereof
HK1249405A1 (en) Anti-dll3 chimeric antigen receptors and methods of use
IL250339A0 (en) Egfrviii specific chimeric antigen receptors for cancer immunotherapy
IL263626A (en) Chimeric antigen receptors and methods for use
IL247172B (en) Cd123 specific chimeric antigen receptors for cancer immunotherapy
IL255336A0 (en) Chimeric antigen receptors and methods of their use
IL247917A0 (en) Cd33 specific chimeric antigen receptors for cancer immunotherapy
PL3443096T3 (en) Compositions and methods for selective expression of chimeric antigen receptors
ZA201608305B (en) Monoclonal antibodies against her2 epitope and methods of use thereof
IL250116B (en) Treatment of cancer using a cll-1 chimeric antigen receptor
IL247898A0 (en) Anti-ox40 antibodies and methods of use
IL273629A (en) Methods of administering chimeric antigen receptor immunotherapy
IL252604B (en) Chimeric antigen receptors and methods of use
ZA201703471B (en) Anti-cldn chimeric antigen receptors and methods of use
IL265438A (en) Chimeric antigen receptors and compositions and methods of use thereof
SG11202010996QA (en) Blockade of cd2 surface expression and expression of chimeric antigen receptors for immunotherapy of t-cell malignancies